Upsher-Smith Labs announced the launch of Pitavastatin Tablets in 1 mg, 2 mg, and 4 mg strengths. The Pitavastatin Tablet market had U.S. sales of approximately $302 million for the 12 months ending August 2023 according to IQVIA. Pitavastatin Tablets are an AB-rated, generic equivalent to the brand product, LIVALO® (pitavastatin) tablets.*
Sawai Group Holdings Co., Ltd.'s (Sawai) company, Sawai USA, Inc. holds the ANDA for Pitavastatin tablets. This marks Sawai's first Paragraph IV product to be launched in the United States market. Upsher-Smith will distribute the product in the U.S.
Product Information
Product, Strength, NDC#, Package Size
- Pitavastatin Tablets, 1 mg, 0832-6048-90, 90-count bottle
- Pitavastatin Tablets, 2 mg, 0832-6049-90, 90-count bottle
- Pitavastatin Tablets, 4 mg, 0832-6050-90, 90-count bottle
For questions about ordering, please call Upsher-Smith at 1-800-654-2299.
Please refer to the full Prescribing Information for Pitavastatin Tablets here. You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information. You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-855-899-9180 or to the FDA by visiting http://www.fda.gov/medwatch.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!